In this study, we found that autocrine CXCL12/CXCR4 was one of the major mechanisms underlying the metastatic property of ECSCs through ERK1/2 signaling pathway, and might serve as a therapeutic target in esophageal cancer patients. Here, MAPK3 is linked to esophageal cancer.